Unknown Effect

Background Information

• Bevacizumab also goes by Avastin

• Has filed for FDA approval for colorectal cancer (source)

• Is an investigational recombinant humanized antibody to vascular endothelial cell growth factor; designed to bind to and inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays a critical role in tumor angiogenesis (the formation of new blood vessels to the tumor) and maintenance of established tumor blood vessels (source)

• Seems to have been used successfully in colorectal and kidney cancers

• NCI/Cancer.gov information page on bevacizumab

• More information

• Article which lists differences between bevacizumab and 2C3 (made by Peregrine)

Research Results

• 2002 abstract which states that sarcomas have a high amount of VEGF

Current Clinical Trials

• Multi-center Phase 2 trial of doxorubicin and bevacizumab for locally recurrent or metastatic soft tissue sarcoma (MSK, Dana-Farber, and Huntsman)